Luciferase Vsv Pseudotype
VSV-G antibody |
|||
70R-VR002 | Fitzgerald | 100 ug | EUR 457.2 |
Description: Affinity purified Rabbit polyclonal VSV-G antibody |
Human IgG antibody Laboratories manufactures the luciferase vsv pseudotype reagents distributed by Genprice. The Luciferase Vsv Pseudotype reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact luciferase assay. Other Luciferase products are available in stock. Specificity: Luciferase Category: Vsv Group: Pseudotype
VSV-G-tag Antibody |
||
Abbexa |
|
|
VSV-g Tag Antibody |
||
Abbexa | 400 ul | EUR 627.6 |
VSV-g Tag Antibody |
||
Abbexa | 80 µl | EUR 343.2 |
VSV-G Tag Antibody |
||
NSJ Bioreagents | 100ul | EUR 356.15 |
Description: Epitope tags consisting of short sequences recognized by well-characterizated antibodies have been widely used in the study of protein expression in various systems. |
Human True insulin ELISA kit |
||
BlueGene | 192 tests | EUR 1524 |
Description: A competitive ELISA for quantitative measurement of Human True insulin in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Human True insulin ELISA kit |
||
BlueGene | 1 plate of 48 wells | EUR 624 |
Description: A competitive ELISA for quantitative measurement of Human True insulin in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Human True insulin ELISA kit |
||
BlueGene | 1 plate of 96 wells | EUR 822 |
Description: A competitive ELISA for quantitative measurement of Human True insulin in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Spike (BQ.1.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter) |
|||
78698-2 | BPS Bioscience | 500 µl x 2 | EUR 4195 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of May 2022, Omicron variants were divided into seven distinct sub-lineages: BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4, and BA.5. As of October 2022, several new BA.5 sub-lineages (e.g. BQ.1, BQ.1.1, BF.7) have been designated._x000D_The spike protein of BQ.1.1 omicron variant has additional mutations (R346T, K444T and N460K) based on the BA.5 variant. The Spike (BQ.1.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BQ.1.1 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter (Figure 1), therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BQ.1.1, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron BQ.1.1 variant in a Biosafety Level 2 facility._x000D_
|
Spike (BF.7, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter) |
|||
78699-1 | BPS Bioscience | 100 µl | EUR 835 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of May 2022, Omicron variants were divided into seven distinct sub-lineages: BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4, and BA.5. As of October 2022, several new BA.5 sub-lineages (e.g. BQ.1, BQ.1.1, BF.7) have been designated._x000D_The spike protein of BF.7 omicron variant has additional mutation R346T based on the BA.5 variant. The Spike (BF.7, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BF.7 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter (Figure 1), therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BF.7, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron BF.7 variant in a Biosafety Level 2 facility._x000D_
|
Spike (BF.7, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter) |
|||
78699-2 | BPS Bioscience | 500 µl x 2 | EUR 4195 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of May 2022, Omicron variants were divided into seven distinct sub-lineages: BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4, and BA.5. As of October 2022, several new BA.5 sub-lineages (e.g. BQ.1, BQ.1.1, BF.7) have been designated._x000D_The spike protein of BF.7 omicron variant has additional mutation R346T based on the BA.5 variant. The Spike (BF.7, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BF.7 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter (Figure 1), therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BF.7, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron BF.7 variant in a Biosafety Level 2 facility._x000D_
|
Spike (XBB.1.5, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter) |
|||
78736-1 | BPS Bioscience | 100 µl | EUR 875 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and human ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of May 2022, Omicron variants were divided into seven distinct sub-lineages: BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4, and BA.5. As of January 2023, additional new sub-lineages (e.g. BQ.1, BQ.1.1, BF.7, XBB.1, XBB.1.5) have been designated._x000D_The Spike (XBB.1.5, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the XBB.1.5 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter (Figure 1), therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (XBB.1.5, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron XBB.1.5 variant in a Biosafety Level 2 facility._x000D_
|
Spike (XBB.1.5, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter) |
|||
78736-2 | BPS Bioscience | 500 µl x 2 | EUR 4405 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and human ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of May 2022, Omicron variants were divided into seven distinct sub-lineages: BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4, and BA.5. As of January 2023, additional new sub-lineages (e.g. BQ.1, BQ.1.1, BF.7, XBB.1, XBB.1.5) have been designated._x000D_The Spike (XBB.1.5, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the XBB.1.5 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter (Figure 1), therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (XBB.1.5, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron XBB.1.5 variant in a Biosafety Level 2 facility._x000D_
|
pPACK-SPIKE SARS-CoV-2 “S” Pseudotype Lentivector Packaging Mix |
|||
CVD19-500A-1 | SBI | 10 rxn | EUR 677 |
pPACK-SPIKE SARS-CoV-2 “S” Pseudotype Lentivector Packaging Mix |
|||
CVD19-510A-1 | SBI | 25 rxn | EUR 1349 |
pPACK-SPIKE B.1.525, SARS-CoV-2 "S" Pseudotype - B.1.525 Variant - Lentivector Packaging Mix |
|||
CVD19-620A-1 | SBI | 10 rxn | EUR 677 |
pPACK-SPIKE B.1.525, SARS-CoV-2 "S" Pseudotype - B.1.525 Variant - Lentivector Packaging Mix (XL) |
|||
CVD19-625A-1 | SBI | 25 rxn | EUR 1349 |
pPACK-SPIKE B.1.429, SARS-CoV-2 "S" Pseudotype - B.1.429 (CAL.20C) Variant - Lentivector Packaging Mix |
|||
CVD19-610A-1 | SBI | 10 rxn | EUR 677 |
pPACK-SPIKE B.1.429, SARS-CoV-2 "S" Pseudotype - B.1.429 (CAL.20C) Variant - Lentivector Packaging Mix (XL) |
|||
CVD19-615A-1 | SBI | 25 rxn | EUR 1349 |
pPACK-SPIKE D614G, SARS-CoV-2 “S” Pseudotype – D614G Mutant – Lentivector Packaging Mix |
|||
CVD19-530A-1 | SBI | 10 rxn | EUR 677 |
pPACK-SPIKE N501Y SARS-CoV-2 “S” Pseudotype – N501Y Mutant – Lentivector Packaging Mix |
|||
CVD19-560A-1 | SBI | 10 rxn | EUR 677 |
pPACK-SPIKE D614G, SARS-CoV-2 “S” Pseudotype – D614G Mutant – Lentivector Packaging Mix (XL) |
|||
CVD19-540A-1 | SBI | 25 rxn | EUR 1349 |
pPACK-SPIKE N501Y SARS-CoV-2 “S” Pseudotype – N501Y Mutant – Lentivector Packaging Mix (XL) |
|||
CVD19-570A-1 | SBI | 25 rxn | EUR 1349 |
pPACK-SPIKE Beta (B.1.351), SARS-CoV-2 "S" Pseudotype - Beta (B.1.351) Variant - Lentivector Packaging Mix |
|||
CVD19-640A-1 | SBI | 10 rxn | EUR 677 |
pPACK-SPIKE Beta (B.1.351), SARS-CoV-2 "S" Pseudotype - Beta (B.1.351) Variant - Lentivector Packaging Mix (XL) |
|||
CVD19-645A-1 | SBI | 25 rxn | EUR 1349 |